Research Calls I
-
Upgrades:
- American Tower (AMT) upgraded to Outperform from Market Perform at Bernstein, tgt $207
- Assured Guaranty (AGO) upgraded to Buy from Neutral at UBS, tgt $94
- Credicorp (BAP) upgraded to Buy from Hold at HSBC, tgt $350
- Jazz Pharmaceuticals (JAZZ) upgraded to Buy from Neutral at UBS, tgt $307
- Progyny (PGNY) upgraded to Buy from Hold at Canaccord, tgt $30
- StubHub Holdings (STUB) upgraded to Buy from Neutral at Guggenheim, tgt $12.50
- American Tower (AMT) upgraded to Outperform from Market Perform at Bernstein, tgt $207
-
Downgrades:
- Biofrontera (BFRI) downgraded to Speculative Buy from Buy at Benchmark, tgt $3
- CrowdStrike (CRWD) downgraded to Sell from Buy at DZ Bank, tgt $500
- Fortinet (FTNT) downgraded to Hold from Buy at DZ Bank, tgt $125
- James River Group Holdings (JRVR) downgraded to Neutral from Buy at UBS, tgt $4.75
- The Hanover Insurance Group (THG) downgraded to Market Perform from Outperform at BMO Capital, tgt $203
- Biofrontera (BFRI) downgraded to Speculative Buy from Buy at Benchmark, tgt $3
-
Others:
- Alnylam Pharmaceuticals (ALNY) initiated with a Buy at Citigroup, tgt $380
- Ascendis Pharma (ASND) initiated with a Buy at Citigroup, tgt $355
- BioMarin Pharmaceutical (BMRN) initiated with a Buy at Citigroup, tgt $75
- BridgeBio Pharma (BBIO) initiated with a Neutral at Citigroup, tgt $82
- CG Oncology (CGON) initiated with a Peer Perform at Wolfe Research
- Corpay (CPAY) initiated with a Buy at Loop Capital, tgt $406
- CytomX Therapeutics (CTMX) initiated with an Outperform at Wolfe Research, tgt $6
- Cytokinetics (CYTK) initiated with a Buy at Citigroup, tgt $99
- Interface (TILE) initiated with a Buy at Benchmark, tgt $36
- Ionis Pharmaceuticals (IONS) initiated with a Buy at Citigroup, tgt $115
- Lightspeed POS (LSPD) reinstated with an Underperform at BofA Securities, tgt $10
- Mirum Pharmaceuticals (MIRM) initiated with an Outperform at Wolfe Research, tgt $145
- NeOnc Technologies (NTHI) initiated with a Buy at Alliance Global, tgt $13
- Oklo (OKLO) initiated with a Peer Perform at Wolfe Research
- Pilgrim's Pride (PPC) reinstated with a Neutral at UBS, tgt $30
- Rapport Therapeutics (RAPP) assumed with a Buy at Truist, tgt $56
- Tyra Biosciences (TYRA) initiated with a Peer Perform at Wolfe Research
- X-energy (XE) initiated with a Hold at Jefferies, tgt $28
- X-energy (XE) initiated with a Buy at Guggenheim, tgt $57
- X-energy (XE) initiated with a Buy at TD Cowen, tgt $35
- X-energy (XE) initiated with a Buy at UBS, tgt $40
- X-energy (XE) initiated with an Overweight at JPMorgan, tgt $38
- X-energy (XE) initiated with an Overweight at Morgan Stanley, tgt $41
- X-energy (XE) initiated with a Peer Perform at Wolfe Research
- Zeta Global Holdings (ZETA) reinstated with a Buy at BofA Securities, tgt $24
- Alnylam Pharmaceuticals (ALNY) initiated with a Buy at Citigroup, tgt $380